# Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment

> **NCT04256577** · — · UNKNOWN · sponsor: **Assiut University** · enrollment: 90 (estimated)

## Conditions studied

- Systemic Lupus

## Interventions

- **DIAGNOSTIC_TEST:** serum ceramides level in blood

## Key facts

- **NCT ID:** NCT04256577
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02
- **Primary completion:** 2021-02
- **Final completion:** 2021-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04256577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04256577, "Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04256577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*